Beauchamp G, Lavoie P A, Elie R
Département de pharmacologie, Université de Montréal, QC, Canada.
Can J Physiol Pharmacol. 1995 May;73(5):619-23. doi: 10.1139/y95-078.
This study was conducted to investigate the inhibition of synaptosomal 45Ca uptake by desipramine and its major metabolite 2-hydroxydesipramine in the rat hippocampus and cingulate cortex, areas associated with emotional control. A concentration-dependent inhibition of net depolarization-induced 45Ca uptake was observed for desipramine (20-200 microM) in synaptosomes from both sites. However, 20 microM 2-hydroxydesipramine failed to inhibit calcium channel function in either of the two limbic sites; higher concentrations (60 or 200 microM) did produce a minor degree of inhibition in hippocampus synaptosomes. Others have shown that the clinically encountered plasma concentrations of 2-hydroxydesipramine are lower than those of desipramine, and the brain concentration of 2-hydroxydesipramine is therefore not expected to surpass or even reach 20 microM. In view of the previously observed clinical activity of 2-hydroxydesipramine, the present results indicate that calcium channel antagonism may not be the basis for the therapeutic effect of tricyclic antidepressants.
本研究旨在探讨去甲丙咪嗪及其主要代谢产物2-羟基去甲丙咪嗪对大鼠海马和扣带回皮质(与情绪控制相关的脑区)突触体45Ca摄取的抑制作用。在来自这两个部位的突触体中,观察到去甲丙咪嗪(20 - 200微摩尔)对去极化诱导的净45Ca摄取具有浓度依赖性抑制作用。然而,20微摩尔的2-羟基去甲丙咪嗪未能抑制这两个边缘脑区中任何一个的钙通道功能;更高浓度(60或200微摩尔)确实在海马突触体中产生了轻微程度的抑制作用。其他人已经表明,临床所遇到的2-羟基去甲丙咪嗪血浆浓度低于去甲丙咪嗪,因此预计2-羟基去甲丙咪嗪的脑内浓度不会超过甚至达到20微摩尔。鉴于先前观察到的2-羟基去甲丙咪嗪的临床活性,目前的结果表明钙通道拮抗作用可能不是三环类抗抑郁药治疗效果的基础。